Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Dec 31;17(12):10605-10608.
doi: 10.21037/jtd-2025-1908. Epub 2025 Dec 24.

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Kimio Yonesaka  1
Affiliations
Editorial

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Kimio Yonesaka. J Thorac Dis. .
No abstract available

Keywords: BRAF V600E; binimetinib; encorafenib; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1908/coif). K.Y. receives funding from Daiichi Sankyo Co., Ltd., and Honoraria for lectures from Chugai Pharmaceutical Co., Ltd., AstraZeneca, Amgen Inc., and Pfizer R&D Japan G.K. He has issued and pending patents with Daiichi Sankyo Co., Ltd. The author has no other conflicts of interest to declare.

Comment on

References

    1. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: non-small cell lung cancer. version 8; 2025.
    1. Reuss JE, Kuruvilla S, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol 2025;43:e31-44. 10.1200/JCO-25-01061 - DOI - PubMed
    1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006. 10.1001/jama.2014.3741 - DOI - PMC - PubMed
    1. Planchard D, Sanborn RE, Negrao MV, et al. BRAF(V600E)-mutant metastatic NSCLC: disease overview and treatment landscape. NPJ Precis Oncol 2024;8:90. 10.1038/s41698-024-00552-7 - DOI - PMC - PubMed
    1. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603-15. - PubMed